

# Glucokinase - Pipeline Review, H1 2020

<https://marketpublishers.com/r/G876E9B41A45EN.html>

Date: May 2020

Pages: 67

Price: US\$ 3,500.00 (Single User License)

ID: G876E9B41A45EN

## Abstracts

Glucokinase - Pipeline Review, H1 2020

### SUMMARY

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Glucokinase – Pipeline Review, H1 2020, outlays comprehensive information on the Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) – Glucokinase is an enzyme that catalyzes the initial step in utilization of glucose by the beta-cell and liver at physiological glucose concentration. The role of GCK is to provide G6P for the synthesis of glycogen. Pancreatic glucokinase plays an important role in modulating insulin secretion. Hepatic glucokinase helps to facilitate the uptake and conversion of glucose by acting as an insulin-sensitive determinant of hepatic glucose usage. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 1 and 6 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Metabolic Disorders which include indications Type 2 Diabetes, Type 1 Diabetes (Juvenile Diabetes), Diabetes and Obesity.

Furthermore, this report also reviews key players involved in Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial

registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## **SCOPE**

The report provides a snapshot of the global therapeutic landscape for Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2)

The report reviews Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics and enlists all their major and minor projects

The report assesses Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Overview

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Therapeutics  
Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Therapeutics  
Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Companies  
Involved in Therapeutics Development

Eli Lilly and Co

Hua Medicine Shanghai Ltd

Impetis Biosciences Ltd

Kriya Therapeutics

Ligand Pharmaceuticals Inc

Merck & Co Inc

Pfizer Inc

Sanwa Kagaku Kenkyusho Co Ltd

Teijin Pharma Ltd

vTv Therapeutics Inc

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Drug Profiles  
dorzagliatin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate Glucokinase and Insulin for Diabetes and Obesity - Drug  
Profile

Product Description

Mechanism Of Action

R&D Progress

GKM-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KTA-112 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Dormant Products

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Discontinued Products

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Product

Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Indication, H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Number of Products under Investigation by Universities/Institutes, H1 2020

Products under Investigation by Universities/Institutes, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Pipeline by Eli Lilly and Co, H1 2020

Pipeline by Hua Medicine Shanghai Ltd, H1 2020

Pipeline by Impetis Biosciences Ltd, H1 2020

Pipeline by Kriya Therapeutics, H1 2020

Pipeline by Ligand Pharmaceuticals Inc, H1 2020

Pipeline by Merck & Co Inc, H1 2020

Pipeline by Pfizer Inc, H1 2020

Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, H1 2020

Pipeline by Teijin Pharma Ltd, H1 2020

Pipeline by vTv Therapeutics Inc, H1 2020

Dormant Projects, H1 2020

Discontinued Products, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

### COMPANIES MENTIONED

Eli Lilly and Co

Hua Medicine Shanghai Ltd

Impetis Biosciences Ltd

Kriya Therapeutics

Ligand Pharmaceuticals Inc

Merck & Co Inc

Pfizer Inc

Sanwa Kagaku Kenkyusho Co Ltd

Teijin Pharma Ltd

vTv Therapeutics Inc

## I would like to order

Product name: Glucokinase - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/G876E9B41A45EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G876E9B41A45EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970